Stock NNVC NANOVIRICIDES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News NanoViricides, Inc.

Equities

NNVC

US6300873022

Market Closed - Nyse
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
1.72 USD -0.58% Intraday chart for NanoViricides, Inc. -5.49% +68.63%
06-20 Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model CI
06-11 Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
CI
Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
CI
NanoViricides - The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect, A First-In-Class, Broad-Spectrum Antiviral Agent
AQ
NanoViricides, Inc. Reports on the Highly Desirable Blood Concentration Profile of its Lead Clinical Stage Broad-Spectrum Antiviral Agent NV-387 Upon Intravenous
CI
NanoViricides, Inc. - A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More, Novel Host-Mimetic, Virus Killing Technology Platform
AQ
NanoViricides, Inc. Intends to Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
CI
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
AQ
NanoViricides Has Filed its Quarterly Report, NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection
AQ
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
NanoViricides: Fiscal Q3 Earnings Snapshot
AQ
NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV
CI
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference on May 15 in New York City
AQ
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
CI
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A
CI
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
AQ
NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon
CI
NanoViricides: Fiscal Q2 Earnings Snapshot
AQ
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications beyond COVID Treatment, Explains NanoViricides, NV-387 Could be As Revolutionary as Antibiotics
AQ
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NNVC Stock
  4. News NanoViricides, Inc.